close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

12.44 +0.26 (+2.13%)
Streaming Delayed Price Updated: 10:54 AM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,483
Open 12.04
Bid (Size) 12.44 (300)
Ask (Size) 12.49 (100)
Prev. Close 12.18
Today's Range 11.67 - 12.61
52wk Range 3.850 - 17.25
Shares Outstanding 55,945,551
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
From Design Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+36.7%
+36.7%
1 Month
-16.2%
-16.2%
3 Month
-5.5%
-5.5%
6 Month
+19.5%
+19.5%
1 Year
+214.1%
+214.1%

More News

Read More
News headline image
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
What to Know About This Fund's $10 Million Bet on Gold Miners ↗
Via The Motley Fool
Topics Economy
News headline image
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
From Design Therapeutics, Inc.
Via GlobeNewswire
Which stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller ↗
Via Benzinga
News headline image
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Design Therapeutics, Inc. - Common Stock publicly traded?
Yes, Design Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Design Therapeutics, Inc. - Common Stock trade on?
Design Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Design Therapeutics, Inc. - Common Stock?
The ticker symbol for Design Therapeutics, Inc. - Common Stock is DSGN on the Nasdaq Stock Market
What is the current price of Design Therapeutics, Inc. - Common Stock?
The current price of Design Therapeutics, Inc. - Common Stock is 12.44
When was Design Therapeutics, Inc. - Common Stock last traded?
The last trade of Design Therapeutics, Inc. - Common Stock was at 08/03/26 10:54 AM ET
What is the market capitalization of Design Therapeutics, Inc. - Common Stock?
The market capitalization of Design Therapeutics, Inc. - Common Stock is 695.96M
How many shares of Design Therapeutics, Inc. - Common Stock are outstanding?
Design Therapeutics, Inc. - Common Stock has 696M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.